Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting. [electronic resource]
Producer: 19970616Description: 1965-73 p. digitalISSN:- 0732-183X
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- CA-125 Antigen -- blood
- Carcinoma -- blood
- Cisplatin -- administration & dosage
- Disease Progression
- Female
- Filgrastim
- Granulocyte Colony-Stimulating Factor -- administration & dosage
- Humans
- Middle Aged
- Neutropenia -- chemically induced
- Ovarian Neoplasms -- blood
- Paclitaxel -- administration & dosage
- Peripheral Nervous System Diseases -- chemically induced
- Recombinant Proteins
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.